Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Usefulness of chemotherapy beyond the second line for metastatic breast cancer: a therapeutic challenge.

Vauléon E, Mesbah H, Laguerre B, Gédouin D, Lefeuvre-Plesse C, Levêque J, Audrain O, Kerbrat P.

Cancer Chemother Pharmacol. 2010 May;66(1):113-20. doi: 10.1007/s00280-009-1141-3. Epub 2009 Sep 27.

PMID:
19784837
2.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, Jönsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
3.

Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.

Pentheroudakis G, Fountzilas G, Bafaloukos D, Koutsoukou V, Pectasides D, Skarlos D, Samantas E, Kalofonos HP, Gogas H, Pavlidis N.

Breast Cancer Res Treat. 2006 Jun;97(3):237-44. Epub 2005 Dec 2.

PMID:
16322882
4.

Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors.

Brun B, Benchalal M, Lebas C, Piedbois P, Lin M, Lebourgeois JP.

Cancer. 1997 Jun 1;79(11):2137-46.

PMID:
9179060
5.

[Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].

Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J.

Cancer Radiother. 2004 Jun;8(3):155-67. French.

PMID:
15217583
7.

Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.

Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, et al.

Clin Cancer Res. 1995 Feb;1(2):189-98.

8.

Impact of chemotherapy beyond the first line in patients with metastatic breast cancer.

Dufresne A, Pivot X, Tournigand C, Facchini T, Altweegg T, Chaigneau L, De Gramont A.

Breast Cancer Res Treat. 2008 Jan;107(2):275-9. Epub 2007 Mar 23.

PMID:
17380382
9.

Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.

Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J.

Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1062-73.

PMID:
15234040
10.

Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy.

Pierga JY, Asselain B, Jouve M, Diéras V, Carton M, Laurence V, Girre V, Beuzeboc P, Palangié T, Dorval T, Pouillart P.

Cancer. 2001 Mar 15;91(6):1079-89.

PMID:
11267952
11.
12.

Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.

Gasparini G, Barbareschi M, Boracchi P, Verderio P, Caffo O, Meli S, Dalla Palma P, Marubini E, Bevilacqua P.

Cancer J Sci Am. 1995 Jul-Aug;1(2):131-41.

PMID:
9166466
13.

Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group.

Castiglione-Gertsch M, Tattersall M, Hacking A, Goldhirsch A, Gudgeon A, Gelber RD, Lindtner J, Coates A, Collins J, Isley M, Senn HJ, Rudenstam CM.

Eur J Cancer. 1997 Dec;33(14):2321-5.

PMID:
9616275
14.

Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.

Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H, Tominaga T, Dirix LY, Gion M.

Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11.

PMID:
10198732
15.
16.

Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support.

Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN.

Cancer. 1994 Apr 15;73(8):2157-67. Erratum in: Cancer 1994 Jul 15;74(2):773.

17.
18.

Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line?

Tacca O, LeHeurteur M, Durando X, Mouret-Reynier MA, Abrial C, Thivat E, Bayet-Robert M, Penault-Llorca F, Chollet P.

Cancer Invest. 2009 Jan;27(1):81-5. doi: 10.1080/07357900802290580.

PMID:
19191099
19.

Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.

Nisticò C, Cuppone F, Bria E, Fornier M, Giannarelli D, Mottolese M, Novelli F, Natoli G, Cognetti F, Terzoli E.

Anticancer Drugs. 2006 Nov;17(10):1193-200.

PMID:
17075319
20.

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.

Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.

J Surg Oncol. 2002 May;80(1):4-11.

PMID:
11967899

Supplemental Content

Support Center